ArticleIndian journal of nephrology
Cystatin C: An alternative dialysis adequacy marker in high flux hemodialysis.
Article in Indian journal of nephrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and influencing factors of pruritus in maintenance hemodialysis patients in China: a meta-analysis.BMC nephrology · 2025Pooled it
- Article
- Comparison of clinical therapeutic effects between high-flux dialysis and low-flux dialysis.American journal of translational research · 2026Article
- Increasing the Removal of Large Solutes by Kidney Replacement Therapy.Journal of the American Society of Nephrology : JASN · 2025Review
- Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria.Antibiotics (Basel, Switzerland) · 2023Review
- Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease.Pediatric nephrology (Berlin, Germany) · 2017Observational
- Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional, low flux (LF) dialyzer allows the removal of small molecular solutes like urea and creatinine. High flux (HF) dialyzers allow the effective removal of middle molecules (MM) as well, and are associated with reduced hemodialysis-related morbidity and mortality. Cystatin C has attractive characteristics as a representative MM. The aim of this study was to determine cystatin C reduction ratio (CysCRR) in both LF and HF groups and to compare it with other markers of dialysis adequacy. Thirty-seven patients were subjected to both LF and HF hemodialysis 2 weeks apart. Serum urea, creatinine and cystatin C were measured pre- and post-dialysis. Cystatin C was measured by latex-enhanced immunoturbidimetry. Urea and creatinine reduction ratios were 72.3 ± 14.7% and 62.5 ± 13%, respectively in the LF group. The CysCRR was -9.7 ± 6.7% and 29.2 ± 11% in LF and HF hemodialysis, respectively. The statistically significant decrease in CysCRR in the HF group shows the effective clearance of MM by HF dialyzers. Hence, CysCRR could be applied to measure the MM clearance in HF hemodialysis. This study highlights the significance of cystatin C as an important dialysis adequacy marker replacing the conventional markers such as urea and creatinine in HF hemodialysis. Among the middle molecules cystatin C scores over beta-2 microglobulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.